JPRN-UMIN000006047招募中1 期
Panitumumab monotherapy for gemcitabine, TS-1 and CDDP tolerant or failure unresectable or recurrent cholangiocarcinoma, evaluation of safety and efficiency - Panitumumab monotherapy for gemcitabine, TS-1 and CDDP tolerant or failure unresectable or recurrent cholangiocarcinoma, evaluation of safety and efficiency
Division of Hepato-Biliary Pancreatic Surgery , Tohoku University Hospital0 个研究点目标入组 20 人开始时间: 2011年9月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1)Previous history of chemotherapy with anti-EGFR antibody (2)Tumor is controllable with any other therapy (SD, PR, CR, NE in RECIST ver.1.1) (3)Previous history of infusion reaction by antibody drug (4)Serious complications (e.g. severe hypertension, severe heart failure, severe coronary artery disease, myocardial infarction within 3 months, severe hepatic failure, poorly controlled diabetes, plumonary fibrosis, interstitial pneumonia or renal failure with dialysis) (5) Simultaneous or metachronous (within 5 years) double cancers, with the exception of intramucosal tumor curable with local therapy (6)Pregnant or lactating women or women of childbearing potential (restrict lactating within 8 weeks after last Panitmumab administration) (7)Patient with severe drug allergy (8)Psychosis or severe mental disorder (9)Inadequate physical condition, as diagnosed by primary physician
研究者
相似试验
进行中（未招募）
不适用
Panitumumab in combination with cisplatin/gemcitabine chemotherapy in patients with bile duct cancer - a randomized clinical phase II study - PiCCA Studycholangiocarcinoma / gall bladder carcinomaMedDRA version: 15.0Level: LLTClassification code 10017620Term: Gallbladder carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 15.0Level: LLTClassification code 10008593Term: CholangiocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-018850-11-DEMedizinische Hochschule Hannover (MHH)
已完成
1 期
Gemcitabine/TS-1 combination chemoradiotherapy for unresectable locally advanced pancreatic cancer(Phase I study)nresectable locally advanced pancreatic cancerJPRN-UMIN000005042Osaka Medical Center for Cancer and Cardiovascular Diseases Division of Hepatobiliary and Pancreatic Oncology24
已完成
2 期
Phase II trial of gemcitabine monotherapy in the third or further line for pretreated patients with advanced non-small cell lung canceron-small cell lung cancerJPRN-UMIN000017791Dept.Repiratory Medicine, Osaka Police Hospital21
已完成
4 期
Combination therapy trial of panitumumab(Pmab) with FOLFIRI for inoperable advanced recurrent colorectal cancer first-line chemotherapyadvanced and recurrent colorectal cancerJPRN-UMIN000005196Kyoto Prefectural University of Medicine70
招募中
1 期
Phase1 trial of Panitumumab combined with S-1 and irrinotecan in advanced/metastatic colorectal cancerColorectal CancerJPRN-UMIN000004747Toho University, Ohashi Medical Center12